Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001925680 | SCV002180409 | uncertain significance | Autosomal dominant nonsyndromic hearing loss 1; Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome | 2021-08-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with DIAPH1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces lysine with glutamic acid at codon 824 of the DIAPH1 protein (p.Lys824Glu). The lysine residue is moderately conserved and there is a small physicochemical difference between lysine and glutamic acid. |
Ambry Genetics | RCV004611988 | SCV005104594 | uncertain significance | Inborn genetic diseases | 2024-05-24 | criteria provided, single submitter | clinical testing | The c.2470A>G (p.K824E) alteration is located in exon 17 (coding exon 17) of the DIAPH1 gene. This alteration results from a A to G substitution at nucleotide position 2470, causing the lysine (K) at amino acid position 824 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |